Padmanabh P. Bhatt - 09 Nov 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: Sr. VP of IP, CSO
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 09 Nov 2022
Net transactions value: -$18,012
Form type: 4
Filing time: 14 Nov 2022, 16:00:46 UTC
Previous filing: 05 Aug 2022
Next filing: 15 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$6,468	+700	+43%	$9.24	2,344	09 Nov 2022	Direct	F1
transaction	SUPN	Common Stock	Sale	$24,480	-700	-30%	$34.97	1,644	09 Nov 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Employee Stock Option (Right to Buy)	Options Exercise	$0	-700	-9.3%	$0.000000	6,800	09 Nov 2022	Common Stock	700	$9.24	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.145, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3	The option vested in four equal annual installments beginning on January 21, 2015.